Annual EBITDA
$18.25 B
+$3.57 B+24.34%
31 December 2023
Summary:
Novartis AG annual earnings before interest, taxes, depreciation & amortization is currently $18.25 billion, with the most recent change of +$3.57 billion (+24.34%) on 31 December 2023. During the last 3 years, it has risen by +$1.04 billion (+6.07%). NVS annual EBITDA is now -40.95% below its all-time high of $30.91 billion, reached on 31 December 2021.NVS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$5.61 B
+$365.00 M+6.95%
30 September 2024
Summary:
Novartis AG quarterly earnings before interest, taxes, depreciation & amortization is currently $5.61 billion, with the most recent change of +$365.00 million (+6.95%) on 30 September 2024. Over the past year, it has increased by +$729.00 million (+14.92%). NVS quarterly EBITDA is now -66.04% below its all-time high of $16.53 billion, reached on 31 December 2021.NVS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$19.71 B
+$729.00 M+3.84%
30 September 2024
Summary:
Novartis AG TTM earnings before interest, taxes, depreciation & amortization is currently $19.71 billion, with the most recent change of +$729.00 million (+3.84%) on 30 September 2024. Over the past year, it has increased by +$2.04 billion (+11.53%). NVS TTM EBITDA is now -36.25% below its all-time high of $30.91 billion, reached on 31 December 2021.NVS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NVS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.3% | +14.9% | +11.5% |
| 3 y3 years | +6.1% | +14.9% | +5.0% |
| 5 y5 years | -9.8% | +39.5% | +32.0% |
NVS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -41.0% | +24.3% | -66.0% | +56.0% | -36.3% | +26.1% |
| 5 y | 5 years | -41.0% | +24.3% | -66.0% | +56.0% | -36.3% | +32.0% |
| alltime | all time | -41.0% | +228.4% | -66.0% | +151.1% | -36.3% | +1413.1% |
Novartis AG EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $5.61 B(+7.0%) | $19.71 B(+3.8%) |
| June 2024 | - | $5.25 B(+12.5%) | $18.98 B(+3.6%) |
| Mar 2024 | - | $4.66 B(+11.5%) | $18.33 B(+0.4%) |
| Dec 2023 | $18.25 B(+24.3%) | $4.18 B(-14.4%) | $18.25 B(+3.3%) |
| Sept 2023 | - | $4.88 B(+6.2%) | $17.67 B(+7.1%) |
| June 2023 | - | $4.60 B(+0.2%) | $16.49 B(+3.5%) |
| Mar 2023 | - | $4.59 B(+27.6%) | $15.94 B(+2.0%) |
| Dec 2022 | $14.68 B(-52.5%) | $3.60 B(-3.0%) | $15.63 B(-45.3%) |
| Sept 2022 | - | $3.71 B(-8.4%) | $28.56 B(-4.0%) |
| June 2022 | - | $4.05 B(-5.4%) | $29.73 B(-3.6%) |
| Mar 2022 | - | $4.28 B(-74.1%) | $30.84 B(-0.2%) |
| Dec 2021 | $30.91 B(+79.6%) | $16.53 B(+238.4%) | $30.91 B(+64.8%) |
| Sept 2021 | - | $4.88 B(-5.2%) | $18.76 B(+2.9%) |
| June 2021 | - | $5.15 B(+18.4%) | $18.23 B(+5.4%) |
| Mar 2021 | - | $4.35 B(-0.6%) | $17.29 B(+0.5%) |
| Dec 2020 | $17.21 B(+10.2%) | $4.38 B(+0.6%) | $17.21 B(+2.9%) |
| Sept 2020 | - | $4.35 B(+3.4%) | $16.73 B(+2.0%) |
| June 2020 | - | $4.21 B(-1.4%) | $16.41 B(+2.0%) |
| Mar 2020 | - | $4.27 B(+9.5%) | $16.08 B(+3.0%) |
| Dec 2019 | $15.62 B(-22.8%) | $3.90 B(-3.1%) | $15.62 B(+4.6%) |
| Sept 2019 | - | $4.03 B(+3.6%) | $14.93 B(+1.2%) |
| June 2019 | - | $3.88 B(+2.0%) | $14.75 B(-28.0%) |
| Mar 2019 | - | $3.81 B(+18.3%) | $20.48 B(+1.2%) |
| Dec 2018 | $20.24 B(+38.7%) | $3.22 B(-16.3%) | $20.24 B(+2.2%) |
| Sept 2018 | - | $3.85 B(-60.0%) | $19.81 B(-1.3%) |
| June 2018 | - | $9.61 B(+169.8%) | $20.07 B(+54.8%) |
| Mar 2018 | - | $3.56 B(+27.8%) | $12.97 B(+12.5%) |
| Dec 2017 | $14.59 B(+0.1%) | $2.79 B(-32.2%) | $11.53 B(-1.4%) |
| Sept 2017 | - | $4.11 B(+64.0%) | $11.69 B(+1.3%) |
| June 2017 | - | $2.51 B(+17.9%) | $11.54 B(-9.8%) |
| Mar 2017 | - | $2.13 B(-27.8%) | $12.79 B(-12.2%) |
| Dec 2016 | $14.57 B(+2.2%) | $2.95 B(-25.5%) | $14.57 B(+2.3%) |
| Sept 2016 | - | $3.96 B(+5.2%) | $14.23 B(+2.0%) |
| June 2016 | - | $3.76 B(-3.8%) | $13.96 B(-0.5%) |
| Mar 2016 | - | $3.91 B(+49.4%) | $14.03 B(-1.6%) |
| Dec 2015 | $14.26 B(-19.2%) | $2.61 B(-28.9%) | $14.26 B(-9.8%) |
| Sept 2015 | - | $3.68 B(-3.9%) | $15.81 B(-7.1%) |
| June 2015 | - | $3.83 B(-7.5%) | $17.02 B(-3.7%) |
| Mar 2015 | - | $4.14 B(-0.6%) | $17.67 B(+0.1%) |
| Dec 2014 | $17.66 B(+11.1%) | $4.17 B(-14.6%) | $17.66 B(+3.3%) |
| Sept 2014 | - | $4.88 B(+8.8%) | $17.09 B(+7.1%) |
| June 2014 | - | $4.49 B(+8.9%) | $15.97 B(+1.0%) |
| Mar 2014 | - | $4.12 B(+14.5%) | $15.80 B(-0.5%) |
| Dec 2013 | $15.89 B(-3.1%) | $3.60 B(-4.1%) | $15.89 B(-0.8%) |
| Sept 2013 | - | $3.75 B(-13.2%) | $16.02 B(-2.6%) |
| June 2013 | - | $4.33 B(+2.8%) | $16.46 B(-1.1%) |
| Mar 2013 | - | $4.21 B(+12.8%) | $16.64 B(+1.5%) |
| Dec 2012 | $16.40 B | $3.73 B(-11.0%) | $16.40 B(+4.7%) |
| Sept 2012 | - | $4.19 B(-7.1%) | $15.66 B(-2.1%) |
| June 2012 | - | $4.51 B(+13.7%) | $16.00 B(-1.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $3.97 B(+32.7%) | $16.31 B(-4.6%) |
| Dec 2011 | $17.09 B(+8.1%) | $2.99 B(-34.1%) | $17.09 B(-2.2%) |
| Sept 2011 | - | $4.53 B(-5.9%) | $17.48 B(+1.8%) |
| June 2011 | - | $4.82 B(+1.4%) | $17.16 B(+6.3%) |
| Mar 2011 | - | $4.75 B(+40.9%) | $16.14 B(+2.1%) |
| Dec 2010 | $15.81 B(+23.8%) | $3.37 B(-20.1%) | $15.81 B(-0.4%) |
| Sept 2010 | - | $4.22 B(+11.1%) | $15.88 B(+6.3%) |
| June 2010 | - | $3.80 B(-14.2%) | $14.94 B(+4.7%) |
| Mar 2010 | - | $4.42 B(+28.7%) | $14.27 B(+11.7%) |
| Dec 2009 | $12.77 B(+2.5%) | $3.44 B(+4.9%) | $12.77 B(+9.0%) |
| Sept 2009 | - | $3.28 B(+4.8%) | $11.72 B(-0.8%) |
| June 2009 | - | $3.13 B(+6.8%) | $11.82 B(-1.3%) |
| Mar 2009 | - | $2.93 B(+22.8%) | $11.98 B(-1.6%) |
| Dec 2008 | $12.46 B(+17.7%) | $2.39 B(-29.3%) | $12.17 B(+3.0%) |
| Sept 2008 | - | $3.38 B(+2.7%) | $11.82 B(+3.3%) |
| June 2008 | - | $3.29 B(+5.3%) | $11.44 B(+6.2%) |
| Mar 2008 | - | $3.12 B(+53.4%) | $10.78 B(+2.3%) |
| Dec 2007 | $10.58 B(+3.9%) | $2.04 B(-32.1%) | $10.53 B(-7.3%) |
| Sept 2007 | - | $3.00 B(+14.1%) | $11.36 B(+4.2%) |
| June 2007 | - | $2.63 B(-8.7%) | $10.91 B(+1.4%) |
| Mar 2007 | - | $2.88 B(+0.3%) | $10.76 B(+3.8%) |
| Dec 2006 | $10.18 B(+16.0%) | $2.87 B(+12.8%) | $10.37 B(+5.9%) |
| Sept 2006 | - | $2.54 B(+2.8%) | $9.79 B(+1.6%) |
| June 2006 | - | $2.47 B(-0.5%) | $9.63 B(+3.5%) |
| Mar 2006 | - | $2.49 B(+8.7%) | $9.30 B(+5.9%) |
| Dec 2005 | $8.78 B(+10.2%) | $2.29 B(-4.1%) | $8.78 B(+3.3%) |
| Sept 2005 | - | $2.39 B(+11.3%) | $8.50 B(+4.2%) |
| June 2005 | - | $2.14 B(+9.1%) | $8.16 B(+0.4%) |
| Mar 2005 | - | $1.97 B(-2.2%) | $8.13 B(+2.0%) |
| Dec 2004 | $7.97 B(+9.8%) | $2.01 B(-1.8%) | $7.97 B(-0.2%) |
| Sept 2004 | - | $2.05 B(-3.0%) | $7.98 B(+2.8%) |
| June 2004 | - | $2.11 B(+17.0%) | $7.77 B(+4.8%) |
| Mar 2004 | - | $1.80 B(-10.9%) | $7.41 B(+2.0%) |
| Dec 2003 | $7.26 B(+1.0%) | $2.02 B(+10.5%) | $7.26 B(-8.1%) |
| Sept 2003 | - | $1.83 B(+4.5%) | $7.90 B(+4.6%) |
| June 2003 | - | $1.75 B(+5.9%) | $7.56 B(+4.3%) |
| Mar 2003 | - | $1.66 B(-37.9%) | $7.25 B(-30.6%) |
| Dec 2002 | $7.19 B(+20.9%) | $2.67 B(+79.5%) | $10.45 B(-796.4%) |
| Sept 2002 | - | $1.49 B(+3.1%) | -$1.50 B(-158.0%) |
| June 2002 | - | $1.44 B(-70.3%) | $2.59 B(+22.2%) |
| Mar 2002 | - | $4.86 B(-152.3%) | $2.12 B(+24.6%) |
| Dec 2001 | $5.95 B(+5.7%) | -$9.29 B(-266.6%) | $1.70 B(>+9900.0%) |
| Sept 2001 | - | $5.58 B(+474.3%) | $0.00(-100.0%) |
| June 2001 | - | $971.00 M(-78.1%) | -$695.00 M(+4.4%) |
| Mar 2001 | - | $4.44 B(-140.4%) | -$666.00 M(-212.7%) |
| Dec 2000 | $5.63 B(+1.2%) | -$10.99 B(-325.1%) | $591.00 M(-94.9%) |
| Sept 2000 | - | $4.88 B(+388.1%) | $11.58 B(+72.9%) |
| June 2000 | - | $1.00 B(-82.4%) | $6.70 B(+17.6%) |
| Mar 2000 | - | $5.70 B | $5.70 B |
| Dec 1999 | $5.56 B(-7.9%) | - | - |
| Dec 1998 | $6.04 B | - | - |
FAQ
- What is Novartis AG annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Novartis AG?
- What is Novartis AG annual EBITDA year-on-year change?
- What is Novartis AG quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Novartis AG?
- What is Novartis AG quarterly EBITDA year-on-year change?
- What is Novartis AG TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Novartis AG?
- What is Novartis AG TTM EBITDA year-on-year change?
What is Novartis AG annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of NVS is $18.25 B
What is the all time high annual EBITDA for Novartis AG?
Novartis AG all-time high annual earnings before interest, taxes, depreciation & amortization is $30.91 B
What is Novartis AG annual EBITDA year-on-year change?
Over the past year, NVS annual earnings before interest, taxes, depreciation & amortization has changed by +$3.57 B (+24.34%)
What is Novartis AG quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of NVS is $5.61 B
What is the all time high quarterly EBITDA for Novartis AG?
Novartis AG all-time high quarterly earnings before interest, taxes, depreciation & amortization is $16.53 B
What is Novartis AG quarterly EBITDA year-on-year change?
Over the past year, NVS quarterly earnings before interest, taxes, depreciation & amortization has changed by +$729.00 M (+14.92%)
What is Novartis AG TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of NVS is $19.71 B
What is the all time high TTM EBITDA for Novartis AG?
Novartis AG all-time high TTM earnings before interest, taxes, depreciation & amortization is $30.91 B
What is Novartis AG TTM EBITDA year-on-year change?
Over the past year, NVS TTM earnings before interest, taxes, depreciation & amortization has changed by +$2.04 B (+11.53%)